Physician profile
Matthew Else
NPI 1265891212
$10,666.95
in general payments reported to CMS, 2019-2025
44 companies · $708 in 2025
The $708 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $986 · 2021: $1,010 · 2022: $1,774 · 2023: $2,315 · 2024: $3,086 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,109.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,643.04 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,328.59 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,028.03 | 2021-2024 | |
| Amgen INC. | $975.32 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $857.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $518.15 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $435.85 | 2019-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $418.90 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.54 | 2019-2024 | Jardiance, Ofev |
| Gilead Sciences, INC. | $369.05 | 2021-2025 | |
| Corium, LLC | $269.80 | 2023-2024 | Azstarys |
| Allergan, INC. | $266.62 | 2019-2020 | |
| Glaxosmithkline, LLC. | $224.56 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $196.73 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $164.37 | 2021-2023 | Dexcom G6 Transmitter |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Else listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.